Asia On The Move: China Healthcare Reform Head Leaves
This article was originally published in PharmAsia News
Sun Zhigang is leaving his cabinet position in China to become the deputy head of southwestern Guizhou province, leaving many wondering about the future direction of the massive effort to provide universal health coverage, improve quality and reduce costs for China’s population. Personnel changes are also taking place at Sanofi and Eisai in Japan, GSK in Southeast Asia and the Chinese association Sino-PhiRDA.
You may also be interested in...
As the largest manufacturer of active pharmaceutical ingredients globally, China is bracing for more uncertainty amid the global pandemic and fast-changing environment, particularly in the US.
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.